Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood

Abstract Background: The Roche CARDIAC proBNP point-of-care (POC) test is the first test intended for the quantitative determination of N-terminal pro-brain natriuretic peptide (NT-proBNP) in whole blood as an aid in the diagnosis of suspected congestive heart failure, in the monitoring of patients with compensated left-ventricular dysfunction and in the risk stratification of patients with acute coronary syndromes. Methods: A multicentre evaluation was carried out to assess the analytical performance of the POC NT-proBNP test at seven different sites. Results: The majority of all coefficients of variation (CVs) obtained for within-series imprecision using native blood samples was below 10% for both 52 samples measured ten times and for 674 samples measured in duplicate. Using quality control material, the majority of CV values for day-to-day imprecision were below 14% for the low control level and below 13% for the high control level. In method comparisons for four lots of the POC NT-proBNP test with the laboratory reference method (Elecsys proBNP), the slope ranged from 0.93 to 1.10 and the intercept ranged from 1.8 to 6.9. The bias found between venous and arterial blood with the POC NT-proBNP method was ≤5%. All four lots of the POC NT-proBNP test investigated showed excellent agreement, with mean differences of between −5% and +4%. No significant interference was observed with lipaemic blood (triglyceride concentrations up to 6.3mmol/L), icteric blood (bilirubin concentrations up to 582μmol/L), haemolytic blood (haemoglobin concentrations up to 62mg/L), biotin (up to 10mg/L), rheumatoid factor (up to 42IU/mL), or with 50 out of 52 standard or cardiological drugs in therapeutic concentrations. With bisoprolol and BNP, somewhat higher bias in the low NT-proBNP concentration range (<175ng/L) was found. Haematocrit values between 28% and 58% had no influence on the test result. Interference may be caused by human anti-mouse antibodies (HAMA) types 1 and 2. No significant influence on the results with POC NT-proBNP was found using volumes of 140–165μL. High NT-proBNP concentrations above the measuring range of the POC NT-proBNP test did not lead to false low results due to a potential high-dose hook effect. Conclusions: The POC NT-proBNP test showed good analytical performance and excellent agreement with the laboratory method. The POC NT-proBNP assay is therefore suitable in the POC setting. Clin Chem Lab Med 2006;44:1269–77.

[1]  Giulio Guagliumi,et al.  Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). , 2006, The American journal of cardiology.

[2]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[3]  P. Casán,et al.  N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of patients with dyspnoea and ventricular dysfunction , 2004, European journal of heart failure.

[4]  Hugo A. Katus,et al.  Evaluation of a Point-of-Care System for Quantitative Determination of Troponin T and Myoglobin , 2000, Clinical chemistry and laboratory medicine.

[5]  A. Singer,et al.  Point-of-care testing reduces length of stay in emergency department chest pain patients. , 2005, Annals of emergency medicine.

[6]  Bruce A Jones,et al.  Biochemical markers of myocardial injury test turnaround time: a College of American Pathologists Q-Probes study of 7020 troponin and 4368 creatine kinase-MB determinations in 159 institutions. , 2009, Archives of pathology & laboratory medicine.

[7]  T. Bertsch,et al.  Development and calibration of a new point-of-care test for the determination of NT-proBNP in whole blood. , 2007, Clinical laboratory.

[8]  Karl Swedberg,et al.  Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. , 2005, European heart journal.

[9]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .

[10]  J. Clive,et al.  Impact of CK-MB testing policies on hospital length of stay and laboratory costs for patients with myocardial infarction or chest pain. , 1997, Clinical chemistry.

[11]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[12]  L. Wallentin,et al.  ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease. The FRISC II ECG substudy , 2002 .

[13]  G. Keren,et al.  Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. , 2005, Archives of internal medicine.

[14]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[15]  P. Hildebrandt,et al.  Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. , 2002, American heart journal.

[16]  A. Wu,et al.  Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[17]  Robert H. Christenson,et al.  The National Academy of Clinical Biochemistry , 2007 .

[18]  C M Gibson,et al.  Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.

[19]  R. Doughty,et al.  Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. , 2003, Journal of the American College of Cardiology.

[20]  R. Califf,et al.  Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. , 2000, The American journal of cardiology.

[21]  R. Doughty,et al.  Epidemiology of heart failure and ventricular dysfunction , 1998, The Lancet.

[22]  C. Sylvén,et al.  Recalibration of the point-of-care test for CARDIAC T Quantitative with Elecsys Troponin T 3rd generation. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[23]  B. Sobel,et al.  An Improved Basis for Enzymatic Estimation of Infarct Size , 1975, Circulation.

[24]  H. Krumholz.  Time to focus on the more typical heart-failure patients , 1998, The Lancet.

[25]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, New England Journal of Medicine.

[26]  A. Richards,et al.  The Role of the Circulation in Processing pro-Brain Natriuretic Peptide (proBNP) to Amino-Terminal BNP and BNP-32 , 1997, Peptides.

[27]  V. Fairbanks,et al.  Methods for measuring plasma hemoglobin in micromolar concentration compared. , 1992, Clinical chemistry.

[28]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[29]  B. Brodie,et al.  Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. , 1998, Journal of the American College of Cardiology.

[30]  P. Collinson,et al.  Multicenter analytical performance evaluation of the Elecsys® proBNP assay , 2004, Clinical chemistry and laboratory medicine.

[31]  J. Kellett.  The prediction of in-hospital mortality by amino terminal pro-brain natriuretic peptide (NT-proBNP) levels and other independent variables in acutely ill patients with suspected heart disease. , 2005, European journal of internal medicine.

[32]  C Ricós,et al.  Current databases on biological variation: pros, cons and progress. , 1999, Scandinavian journal of clinical and laboratory investigation.

[33]  P. Bettencourt.  NT‐proBNP and BNP: biomarkers for heart failure management , 2004, European journal of heart failure.

[34]  Gerald J Kost,et al.  Point-of-Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers. , 2005, Cardiology clinics.

[35]  R. Califf,et al.  Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. , 1999, Circulation.

[36]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[37]  E. Carson,et al.  A prospective randomized controlled trial of point-of-care testing on the coronary care unit , 2004, Annals of clinical biochemistry.

[38]  Henry Krum,et al.  The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). , 2005, European heart journal.

[39]  K. Blick.  Economics of Point-of-Care (POC) Testing for Cardiac Markers and B-Natriuretic Peptide (BNP) , 2005 .

[40]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[41]  C. Frampton,et al.  Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. , 2003, Journal of the American College of Cardiology.

[42]  P. Grande,et al.  Estimation of Acute Myocardial Infarct Size in Man by Serum CK‐MB Measurements , 1982, Circulation.

[43]  W. Doerfler,et al.  Uptake of foreign DNA from the environment: the gastrointestinal tract and the placenta as portals of entry. , 1998, Wiener klinische Wochenschrift.

[44]  G. Wagner,et al.  Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. , 2003, Journal of the American College of Cardiology.

[45]  T. McDonagh,et al.  N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. , 2005, Journal of cardiac failure.

[46]  M. Frenneaux,et al.  Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche Elecsys system. , 2004, Clinical chemistry.

[47]  Mauro Panteghini,et al.  AACC creatine kinase MB (CK-MB) standardization material used as manufacturer's working calibrator is unable to harmonize CK-MB results between two commercial immunoassays. , 2004, Clinical chemistry.

[48]  J. Parner,et al.  N‐terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF) , 2004, European journal of heart failure.

[49]  F. Apple,et al.  Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[50]  P. Doyle,et al.  Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. , 2003, Clinical chemistry.

[51]  Deepak L. Bhatt,et al.  Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. , 2000, JAMA.

[52]  N. Rifai,et al.  False increase of cardiac troponin I with heterophilic antibodies. , 1998, Clinical chemistry.

[53]  J. Rouleau,et al.  Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure: A Substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial , 2004, Circulation.

[54]  F. Apple,et al.  Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. , 2005, Clinical chemistry.

[55]  A. Scholer,et al.  Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies , 2001, Annals of clinical biochemistry.

[56]  Deepak L. Bhatt,et al.  Utilization of Early Invasive Management Strategies for High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative , 2004 .

[57]  P O Collinson,et al.  Analytical performance of the N terminal pro B type natriuretic peptide (NT‐proBNP) assay on the Elecsys™ 1010 and 2010 analysers , 2004, European journal of heart failure.

[58]  E. Minar,et al.  Multicentre evaluation of a new point-of-care test for the quantitative determination of D-dimer. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[59]  S. Sieck.  The Evolution of a New Standard of Hospital Care: Paradigm Shift to the Emergency Department and the Role of Point-of-Care Testing , 2006 .

[60]  M. Davies,et al.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.

[61]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[62]  A. Dasgupta,et al.  False-positive troponin I in the MEIA due to the presence of rheumatoid factors in serum. Elimination of this interference by using a polyclonal antisera against rheumatoid factors. , 1999, American journal of clinical pathology.

[63]  J. Muhlestein,et al.  An emergency department-based protocol for rapidly ruling out myocardial ischemia reduces hospital time and expense: results of a randomized study (ROMIO). , 1996, Journal of the American College of Cardiology.

[64]  R. Kleiger,et al.  Correction: Outcomes in Patients with Acute Non-Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy. , 1998, The New England journal of medicine.

[65]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. , 2007, Clinical chemistry.